Optimized sample preparation strategy for the analysis of low molecular mass adducts of a fluorescent cisplatin analogue in cancer cell lines by CE‐dual‐LIF
Authors:
- 8 December 2014
- journal article
- research article
- Published by Wiley in Electrophoresis
- Vol. 36 (4) , 509-517
Abstract
Pt‐based anticancer drugs, such as cisplatin, are known to undergo several (bio‐)chemical transformation steps after administration. Hydrolysis and adduct formation with small nucleophiles and larger proteins are their most relevant reactions on the way to the final reaction site (DNA), but there are still many open questions regarding the identity and pharmacological relevance of various proposed adducts and intermediates. Furthermore, the role of buffer components or additives, which are inevitably added to samples during any type of analytical measurement, has been frequently neglected in previous studies. Here, we report on adduct formation reactions of the fluorescent cisplatin analogue carboxyfluorescein diacetate platinum (CFDA‐Pt) in commonly used buffers and cell culture medium. Our results indicate that chelation reactions with noninnocent buffers (e.g., Tris) and components of the cell culture/cell lysis medium must be taken into account when interpreting results. Adduct formation kinetics was followed up to 60 h at nanomolar concentrations of CFDA‐Pt by using CE‐LIF. CE‐MS enabled the online identification of such unexpected adducts down to the nanomolar concentration range. By using an optimized sample preparation strategy, unwanted adducts can be avoided and several fluorescent adducts of CFDA‐Pt are detectable in sensitive and cisplatin‐resistant cancer cell lines. By processing samples rapidly after incubation, we could even identify the initial, but transient, Pt species in the cells as deacetylated CFDA‐Pt with unaltered complexing environment at Pt. Overall, the proposed procedure enables a very sensitive and accurate analysis of low molecular mass Pt species in cancer cells, involving a fast CE‐LIF detection within 5 min.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (WE 2422/7.1)
This publication has 28 references indexed in Scilit:
- Influence of cimetidine and its metabolites on Cisplatin—Investigation of adduct formation by means of electrochemistry/liquid chromatography/electrospray mass spectrometryJournal of Chromatography A, 2013
- Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analoguesJBIC Journal of Biological Inorganic Chemistry, 2012
- Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitinJBIC Journal of Biological Inorganic Chemistry, 2011
- Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugsJournal of Trace Elements in Medicine and Biology, 2010
- Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cellsBMC Cancer, 2008
- Speciation analysis of platinum antitumoral drugs in impacted tissuesTalanta, 2007
- Cisplatin Carbonato Complexes. Implications for Uptake, Antitumor Properties, and ToxicityJournal of the American Chemical Society, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI‐MS: Indications of Guanosine 5′‐Monophosphate O6–N7 ChelationChemBioChem, 2004
- Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometryElectrophoresis, 2001